1 In guinea-pig and canine airway smooth muscle, there is reduced ,-adrenoceptor agonist sensitivity in tissues pre-contracted with muscarinic agonists when compared to tissues pre-contracted with other spasmogens, such as histamine or leukotriene D4. This reduced sensitivity may be the result of an interaction between muscarinic receptors and P-adrenoceptors. In this study the effects of M2 receptor antagonism and stimulation have been investigated on the relaxant potency of isoprenaline in guinea-pig isolated tracheal smooth muscle. 2 (+)-cis-Dioxolane contracted isolated tracheal strips in a concentration-dependent manner (EC50= 11.5 ± 0.9 nM). The rank order of antagonist apparent affinities (with pA2 values in parentheses) was atropine (9.4 ± 0.1) > zamifenacin (8.2 ± 0.1) > para-fluoro-hexahydro-siladiphenidol (p-F-HHSiD, 7.2 ± 0.1) > pirenzepine (6.5 ± 0.1) > methoctramine (5.5 ± 0.1). Schild slopes were not significantly different from unity. This was consistent with a role of muscarinic M3 receptors in mediating contraction. 3 In tissues pre-contracted to 3 g isometric tension using (+)-cis-dioxolane (0.2 gM, approximately EC80), the relaxant potency of isoprenaline was significantly (P< 0.05) increased by 0.3 LM methoctramine (control EC50 = 32.2 ± 4.3 nM, plus methoctramine EC50 = 19.1 ± 4.5 nM). This concentration of methoctramine had no effect on contractile responses to (+)-cis-dioxolane (control, ECm = 17.6 ± 3.2 nM, plus methoctramine, ECm = 21.0 ± 4.4 nM).
Introduction
In guinea-pig and canine airway smooth muscle, the relaxant potency of P-adrenoceptor agonists depends both upon the nature of the agonist used to elevate the resting tension and the magnitude of the contracture from which relaxations are elicited (Torphy, 1984; Russell, 1984; Torphy et al., 1985) . Thus, from equivalent levels of developed isometric tension, isoprenaline is less potent in relaxing tissues pre-contracted with muscarinic agonists than tissues pre-contracted with either histamine or leukotriene D4, (Torphy, 1984; Russell, 1984; Koenig et al., 1989) . One explanation for the difference in isoprenaline relaxant potency, is an inhibitory action of muscarinic receptor stimulation on P-adrenoceptor function (Torphy, 1984; Gunst et al., 1989) .
Activation of muscarinic receptors in smooth muscle re- sults in inhibition of adenylyl cyclase activity and stimulation of phosphoinositide specific phospholipase C activity (Jones et al., 1987; Sankary et al., 1988; Yang et al., 1991; Pyne et I Author for correspondence. al., 1992) . This is due to activation of two muscarinic receptor subtypes, M2 (80-88%) and M3 (12-20%) respectively (Fryer & El Fakahany, 1990; Mahesh et al., 1992) . Muscarinic M3 receptors mediate smooth muscle contraction (Roffel et al., 1990; Ten Berge et al., 1993) , but the role, if any, of the majority M2 receptor population is unclear.
In smooth muscle, adenylyl cylcase activity is enhanced by P-adrenoceptor activation, resulting in relaxation. Activation of muscarinic M2 receptors inhibits this stimulation, by coupling to a pertussis toxin-sensitive guanine nucleotide binding protein, Gi (Sankary et al., 1988; Yang et al., 1991; Griffin & Ehlert, 1992; Pyne et al., 1992) . In canine isolated trachea pre-contracted with muscarinic agonists, selective antagonism of M2 receptors enhances the relaxant potency of isoprenaline (Fernandes et al., 1992) . Pertussis toxin, which ADP-ribosylates and thereby inactivates the alpha subunit of Gi, has a similar effect (Mitchell et al., 1993) . Thus, activation of M2 receptors may attenuate P-adrenoceptor-mediated relaxation, thereby facilitating M3 receptor-mediated contraction (Torphy et al., 1985; Sankary et al., 1988) . Alternatively, it is also possible that attenuation of relaxation to P-adrenoceptor activation involves M3 receptors, directly. Stimulation of M3 receptors activates a phosphoinositide specific phospholipase C, via a pertussis toxin-insensitive G protein, Gq. This results in the formation of inositol (1,4,5) trisphosphate and 1,2 diacylglycerol (see Chilvers & Nahorski, 1990, for review), which causes intracellular release of calcium and activation of a protein kinase C, respectively. These two processes may lead to phosphorylation of Padrenoceptors, guanine nucleotide binding proteins (G.) or adenylyl cyclase (Van Amsterdam et al., 1989; . Functional antagonism by M3 receptor activation may, therefore, offset relaxations to P-adrenoceptor agonists, without involving M2 receptors. In support of this hypothesis, Meurs et al. (1993) have failed to demonstrate an effect of selective M2 receptor antagonism on the relaxant potency of isoprenaline in bovine trachea. However, a correlation was demonstrated by these workers, between the inhibitory effects on the relaxant potency of isoprenaline and the potency at M3 receptors mediating enhanced inositol phospholipid metabolism .
The aim of the present studies was to explore further the role of muscarinic receptor subtypes in modulating relaxations of guinea-pig, isolated trachea to isoprenaline. The lack of potent and selective M2 and M3 receptor agonists (see Caulfield, 1993 , for review) mandated that indirect approaches be employed. These were, firstly, the use of a non-selective muscarinic agonist, (+)-cis-dioxolane, in the presence of selective M2 receptor antagonism using methoctramine. Secondly, the use of tissues pre-contracted with muscarinic agonists possessing varying intrinsic efficacies at muscarinic receptors. Thirdly, by studying the effects of selective M2 receptor stimulation using (+)-cis-dioxolane in the presence of M3 receptor antagonism by p-F-HHSiD (para-fluoro-hexahydrosiladiphenidol). A preliminary account of this work was presented to the British Pharmacological Society (Watson & Eglen, 1993 (pH 7.4, 37C) . This 1 g applied tension was considered the baseline, from which all further tension charges were recorded. Indomethacin (1 lM) was present in the Krebs solution throughout, to inhibit prostaglandin synthesis. Tetrodotoxin (0.1 M) was also present throughout, to eliminate pre-junctional effects of muscarinic agonists. Corticosterone (30tiM) was present in all studies with P-adrenoceptor agonists, to inhibit extraneuronal monoamine uptake. All preparations were allowed 60 min to equilibrate, prior to construction of concentration-effect curves. These were established in a cumulative manner, using incremental concentrations at 0.5 logl0 intervals. Each successive concentration was added once a sustained contracture to the previous concentration was attained.
Receptor characterization
Concentration-effect curves to (+)-cis-dioxolane, were constructed and tissues were washed and re-equilibrated, for 60 min, in the presence of a single concentration of one of the following antagonists: atropine (10, 30 or 100 nM), pirenzepine (1, 3 or 10.M), methoctramine (1, 3 or 1O M), p-F-HHSiD (0.03, 0.3, 1 or 3 AM) and zamifenacin (10-100 nM). A second concentration-effect curve to (+)-cis-dioxolane was then established in the presence of antagonist. Parallel studies were undertaken in the absence of antagonist to correct for temporal changes in sensitivity.
The effect of muscarinic M2 receptor antagonism, on the relaxant potency of isoprenaline in tissues pre-contracted with ( +)-cis-dioxolane A concentration-effect curves was initially obtained to (+)-cis-dioxolane (1 nM-1 I M) in all tissues, to establish both the maximal contractile response and the concentration required to give approximately a 3 g increase in isometric tension. During this initial exposure to (+)-cis-dioxolane, methoctramine (0.3 LM) was present to inhibit M2 receptor desensitization occurring at high (+)-cis-dioxolane concentrations. Tissues were then washed at 15 min intervals over the following 120 min period and during the final 60 min, separate tissues were equilibrated in the absence or presence of a single concentration of methoctramine (0.3 LM). Tissues were then pre-contracted to 3 g using (+)-cis-dioxolane (0.2 gM) and concentration-effect curves to isoprenaline (01. nM-1 tM)
were established.
The effect of muscarinic agonists and histamine on the relaxant potency of isoprenaline Concentration-effect curves to L-660,863 (1 nM-0.3 LM), SDZENS 163 (0.1-30tiM), acetylcholine (ACh, 1 nM-10 LM), (+)-cis-dioxolane (1nM-1lyM) or histamine (0.1-0.3 mM) were obtained to establish both the maximal response to these agonists and the concentration required to increase isometric tension by approximately 3 g. Tissues were then washed at 15 min intervals over a 60 min period and allowed to re-attain baseline isometric tension. The tension was then increased to 3 g by addition of either muscarinic agonist or histamine. Each tissue was exposed to only one agonist. Once a stable contracture was attained, relaxant concentrationeffect curves to isoprenaline (0.1 nM-1 IM) were established. Similar experiments were also undertaken, in separate tissues pre-contracted with a lower concentration of the above agonists, to an isometric tension of 2 g. Physostigmine (Q.3 LM) was present in the studies with acetylcholine, to inhibit acetylcholinesterase activity. The apparent affinity (pA2) of p-F-HHSiD at M2 receptors is 6.0 (Lambrecht et al., 1988; Eglen et al., 1990) . Therefore, at the concentration of p-F-HHSiD (0.3 lAM) used to inhibit M3 receptor-mediated contractions in this experiment, 23% of M2 receptor would be occupied. This level of M2 receptor occupancy may compromise putative inhibitory effects of (+ )-cis-dioxolane on the isoprenaline relaxant potency. Therefore, these experiments were repeated in the absence of p-F-HHSiD. To retain M2 receptor activity but reduce M3 receptor-mediated contractions, the concentration of (+)-cisdioxolane was reduced from 0.1 aM to 30 nM. The final 3 g increase in isometric tension was therefore achieved by a combination of histamine and (+)-cis-dioxolane (test tissues) or histamine alone (control tissues).
Measurement and analysis of responses
All responses were recorded as changes in isometric tension (g). Contractile responses were normalized to the maximal contractile responses in each tissue during the first exposure to agonist. Relaxant responses were expressed as a percentage of the isometric tension induced by the agonist, before application of isoprenaline. Data were analysed by the relationship of Parker & Waud (1971) , using a non-linear iterative curve fitting procedure (Kaleidagraph, Synergy software, Reading, PA 19606, U.S.A., Leung et al., 1992) . The potency (defined as the EC50) and maximal responses determined by this procedure were corrected for changes in sensitivity with time, where necessary. Apparent antagonist affinities (pA2) were determined, where appropriate, by Schild regression analysis (Arunlakshana & Schild, 1959) . Values quoted are those obtained when the slope, not being significantly different from unity, was constrained to unity.
Statistical analysis of the data was performed using paired and unpaired Student's t tests where appropriate, with P< 0.05 being considered significant. All values quoted are the mean ± s.e.mean from five animals, unless otherwise stated. 
Results
Receptor characterization (+)-cis-Dioxolane caused concentration-dependent contractions of tracheal strips with a maximal response of 4.2 ± 0.1 g and potency (ECm,) of 11.5 ± 0.9 nM. No significant timedependent shift in the concentration-effect curves to (+)-cisdioxolane was observed. All muscarinic antagonists caused parallel concentration-dependent dextral shifts in the concentration-effect curves to (+ )-cis-dioxolane. The apparent antagonist affinities (pA2), were atropine 9.4 ± 0.1, pirenzepine 6.5 ± 0.1, methoctramine 5.5 ± 0.1, p-F-HHSiD 7.2 ± 0.1 and zamifenacin 8.2 ± 0.1 The Schild slopes were not significantly different from unity.
The effect of muscarinic M2 receptor antagonism, on the relaxant potency of isoprenaline in tissues pre-contracted with (+)-cis-dioxolane Isoprenaline caused concentration-dependent relaxations in tissues pre-contracted with 0.2 JM (+)-cis-dioxolane to approximately 3 g (Figure 1 ). Isoprenaline completely reversed contractions induced by (+)-cis-dioxolane, with a potency (ECm,) of 32.2 ± 4.3 nM. In the presence of methoctramine (0.3pJM), the concentration-effect curve to isoprenaline was shifted to the left in a parallel fashion (Figure 1 ) with a potency (EC50 value) of 19.1 ± 4.5 nM (P<0.05). There was no significant difference in the magnitude of the developed tension in either of these two groups, prior to performing concentration-effect curves to isoprenaline (2.9 ± 0.2 g controls and 3.2 ± 0.2 g plus methoctramine). There was no significant effect of this concentration of methoctramine (0.3 JAM) on the potency of (+)-cis-dioxolane (control, EC50 = 17.6 ± 3.2 nM, plus methoctramine, EC50 = 21.0 ± 4.4 nM) nor the magnitude of the maximum response to agonist (n = 6).
The effect of muscarinic agonists and histamine on the relaxant potency of isoprenaline All muscarinic agonists produced concentration-dependent contractions of tracheal strips (Table 1) and were full agonists with respect to (+)-cis-dioxolane, with the exception of SDZ ENS 163 ( Figure 2 , Table 1 ). The rank order of potency was L-660,863 > (+ )-cis-dioxolane > ACh > SDZ ENS 163 (Table 1) . Physostigmine (0.3 JM), added 15-20 min prior to the addition of acetylcholine, increased isometric tension by 1.4 ± 0.2 g (see Figure 3) .
Concentration-dependent relaxations to isoprenaline were seen in all tissues pre-contracted to either 3 or 2 g ( Figure 4 , Table 2 ). In tissues pre-contracted with the higher concentration of muscarinic agonist, to approximately 3 g, isoprenaline was most potent when SDZ ENS 163 was used to induce the 
The concentrations of agonist required to achieve these developed (Figures 3 and 4) .
When tissues were pre-contracted with the lower concentration of agonist, to approximately 2g, isoprenaline was again most potent against contractures induced by SDZ ENS 163 and least potent against (+)-cis-dioxolane-induced contracture (Table 2) . Under these conditions, isoprenaline completely reversed the contracture induced by all agonists (Figure 4) 
g).
In tissues pre-contracted to 3 g, isoprenaline was significantly more potent at relaxing tissues contracted by histamine than L-660,863, (+ )-cis-dioxolane or acetylcholine. However, at this level of isometric tension, there was no significant difference between the relaxant potency of isoprenaline in tissues pre-contracted with either histamine or SDZ ENS 163. In tissues pre-contracted to 2 g, there was no significant difference between the potency of isoprenaline in tissues pre-contracted with muscarinic agonists or with histamine. In the presence of p-F-HHSiD (0.3~lm), the relaxant potency (EC.*) of isoprenaline against histamine pre-contracture, was not significantly altered by agonism Of M2 receptors using (+ )-cis-dioxolane (0.1 g~m). Similarly, M2 receptor antagonism using methoctramine (1 fLM), did not significantly alter the relaxant potency of isoprenaline in tissues pre-contracted with histamine in the presence of (+ )-cis-dioxolane ( Figure   5 ; Table 3 ). Despite the presence of 0.3 jLm p-F-HHSiD, (+ )-cis-dioxolane (0.1 j.Lm) caused a significant increase in isometric tension (0.4 ±0.1 g). However, the concentration of histamine used to induce tone was adjusted, such that the magnitude of the contracture prior to performing concentration-effect curves to isoprenaline, was not significantly different between the three groups ( Figure 5 ; Table 3 ).
In the absence of p-F-HHSiD, the relaxant potency of isoprenaline was significantly reduced in tissues pre-contracted to 3 g with a combination of histamine and (+ )-cisdioxolane (30 nm), when compared to tissues pre-contracted to equivalent isometric tension with histamine alone. This effect was reversed by 1.0 .l~m methoctramine ( Figure 5 ; Table  3 ). In the absence of p-F-HHSiD, the increase in isometric tension induced by (+)-cis-dioxolane (30 nm) was 3.1 ± 1.0 g. However, the concentration of histamine used to induce tone was adjusted, such that the magnitude of the contracture prior to performing concentration-effect curves to isoprenaline, was not significantly different between the three groups ( Figure 5 ; Table 3 ).
Discussion
In airway smooth muscle, muscarinic receptors mediate contraction and appear to modulate the relaxant potency of 13-adrenoceptor agonists. In all species studied to date, M2 4.4 ± 0.6 6.7 ± 0.8 3.6 ± 0.9 I -NS I and M3 receptors are present in airway smooth muscle in the ratio approximately 4:1 (Fryer & El Fakahany, 1990; Mahesh et al., 1992) . Both these muscarinic receptor subtypes have been implicated in the muscarinic receptor-mediated inhibition of P-adrenoceptor agonist-mediated relaxation (Van Amsterdam et al., 1989; Fernandes et al., 1992) . The aim of the present study was to characterize further the role of muscarinic M2 receptors in modulating relaxations of guineapig, isolated trachea to isoprenaline. In order to achieve this, three separate approaches were used, after first establishing an affinity profile for a range of muscarinic antagonists at the post-junctional receptor mediating contraction.
Receptor characterization
The antagonist affinity profile was consistent with stimulation of M3 receptors causing contraction with no involvement of M2 receptors (Ten Berge et al., 1993) . The pA2 for the novel M3 receptor antagonist, zamifenacin, was similar to that previously reported by Wallis et al. (1993) . The pA2 value for p-F-HHSiD (7.2) was lower than reported at M3 receptors in other smooth muscles, including guinea-pig ileum (7.8-8.0, Lambrecht et al., 1988) but consistent with previous findings in our laboratory (Eglen et al., 1990) . The M3 receptor in guinea-pig trachea may be atypical, since p-F-HHSiD, RDS 129 (Saihin & Ilhan, 1986 ) and zamifenacin (Wallis et al., 1993 ; this study) discriminate between M3 receptors in guinea-pig trachea and ileum. However, in the absence of evidence for structural heterogeneity of M3 receptors, the reasons for these differences in pA2 values remain unknown (Caulfield, 1993) . A consequence of the atypical nature of the tracheal M3 receptor is that studies attempting to characterize M2 or M3 receptor function alone in this tissue are compromised by the low tracheal M2:M3 selectivity of p-F-HHSiD and zamifenacin.
The effect of muscarinic M2 receptor antagonism on the relaxant potency of isoprenaline in tissues pre-contracted with ( +)-cis-dioxolane
The first approach to study the role of M2 receptors in guinea-pig trachea reproduced the findings of Fernandes and colleagues (1992) in canine trachea. Methoctramine (0.3 rIM) increased the relaxant potency of isoprenaline, in (+)-cisdioxolane pre-contracted tissues. The small but statistically significant increase in isoprenaline relaxant potency (1.7 fold shift) in the presence of methoctramine may be an underestimate, since comparison with the potency of isoprenaline in tissues not previously exposed to methoctramine indicates a 2.6 fold shift induced by methoctramine (see below). As the apparent affinities of methoctramine at M2 and M3 receptors are 7.8 and 5.8, respectively (Melchiorre et al., 1987; Eglen et al., 1988) , it is unlikely that M3 receptor antagonist properties of methoctramine account for the effect observed. To support this conclusion, 0.3 ELM methoctramine had no significant effect on M3-mediated contractile responses (this study). Furthermore, higher concentrations of methoctramine (1 and 3 tiM), which increase M3 receptor occupancy, did not further augment the potency of isoprenaline (data not shown). (Ford et al., 1991) . L-660,863 is a relatively selective muscarinic M2 receptor agonist . However, its efficacy at this receptor is low and therefore, in poorly coupled M2 receptor systems it acts as an antagonist (Freeman et al., 1990; Eglen et al., 1992) . SDZ ENS 163, is a 4. and an M2 receptor antagonist (Enz et al., 1992) . Under the present experimental conditions, agonist effects of SDZ ENS 163 at Ml receptors in the parasympathetic ganglia (Bloom et al., 1987) , were inhibited by the inclusion of tetrodotoxin, while post-junctional Ml receptors have not been detected in airway smooth muscle (Mak & Barnes, 1990) . Therefore, the use of SDZ ENS 163 permitted the relaxant potency of isoprenaline to be assessed under conditions of partial M3 receptor stimulation and M2 receptor antagonism. This agent, unlike L660,863 shows no selectivity between receptor subtypes on the basis of affinity, although it is 'functional selective' (atria M2 -logKB = 5.9 ± 0.2; tracheal -logKA = 5.8 ± 0. 1; Watson & Eglen, 1993) . All compounds were full agonists at M3 receptors mediating contraction of tracheal strips, with the exception of SDZ ENS 163 which acted as a partial agonist. This finding is consistent with previous reports (Eglen et al., 1990; Ford et al., 1991; Enz et al., 1992) . The isoprenaline relaxant potencies were not greatly different between preparations contracted with the muscarinic agonists to 2 g isometric tension. Moreover, the isoprenaline relaxant potencies were not significantly different from potency estimates in tissues pre-contracted with histamine. This suggests that at low concentrations of muscarinic agonists, there is little effect of muscarinic receptor activation on the attenuation of relaxant responses to isoprenaline. Therefore, despite activation of M3 receptors, to elicit a 2 g increase in tension, no inhibition of P-adrenoceptor-mediated relaxant responses could be detected.
However, increasing the level of both M2 and M3 receptor activation, significantly reduced the relaxant potency of isoprenaline. Under this condition, significant differences were seen in the relaxant potency of isoprenaline between tissues pre-contracted with full muscarinic agonists ((+)-cis-dioxolane, acetylcholine and L-660,863) and those pre-contracted with the partial M3 agonist/M2 antagonist, SDZ ENS 163. These differences may suggest that differential agonist activity at M2 or M3 receptors, rather than the developed tension per se, may influence the isoprenaline relaxant potency. In contrast, differences in isoprenaline relaxant potency were not seen in tissues pre-contracted with histamine to 2 or 3 g. Since histamine does not interact at muscarinic receptors, these data implicate a specific role for muscarinic receptors in the attenuation of relaxant responses to isoprenaline, which is in agreement with the work of others (Torphy, 1984; Jones et al., 1987; Fernandes et al., 1992) .
The effect of M2 receptor agonism and antagonism, on the relaxant potency of isoprenaline in tissues pre-contracted with histamine
The final approach in the elucidation of the role of M2 receptors was to stimulate the M2 receptors in the absence of M3 receptor activation. Ideally, an agonist with high potency and selectivity at M2 receptors, which lacks intrinsic efficacy at M3 receptors, is required. However, such a compound is unavailable. Thus, the alternative was to use (+)-cis-dioxolane, to activate M2 receptors, in the presence of M3 receptor antagonism by p-F-HHSiD. In this manner, the effect of M2 receptor activation on relaxant potency of isoprenaline was examined in tissues pre-contracted to 3 g using histamine in the presence of 0.3 ILM p-F-HHSiD. Under these conditions, there was no effect of (+ )-cis-dioxolane on the relaxant potency of isoprenaline. This finding may imply that activation of M3 receptors is required to mediate the reduction in isoprenaline relaxant potency, supporting conclusions reached by Meurs et al. (1993) .
Alternatively, an involvement of M2 receptors cannot be excluded, since in guinea-pig trachea, p-F-HHSiD shows relatively low selectivity between M3 and M2 receptors (16 fold Eglen et al., 1990) . Assuming a pA2 of 6.0 for p-FHHSiD (Lambrecht et al., 1988; Eglen et al., 1990 ) 23% of M2 receptors would be occupied at the concentration required to antagonize M3 receptor-mediated contractions (0.3 ILM). This may be sufficient, in a poorly coupled system, to antagonize the effect of M2 receptor-mediated inhibition of isoprenaline-induced relaxations. In an attempt to clarify the problem, experiments were repeated in the absence of p-FHHSiD, and with a lower concentration of (+ )-cis-dioxolane (30 nM), to reduce effects at M3 receptors, while maintaining detectable effects on isoprenaline relaxant potency. In these studies, (+)-cis-dioxolane reduced the relaxant potency of isoprenaline, an effect which was reversed by methoctramine. The modest effect of (+ )-cis-dioxolane (30 nM) was unsurprising given our previous observations that low concentrations of muscarinic agonists have small effects on isoprenaline relaxant potency. Taken together these data may suggest that the level of isometric tension achieved, is less important in determining the relaxant potency of isoprenaline compared to the level of muscarinic receptor activation.
Some data obtained in these studies require further explanation; (1) In the first study, an equilibration step with methoctramine, was used during construction of concentration-effect curves to (+)-cis-dioxolane. As discussed above, in tissues treated in this way, the relaxant potency of isoprenaline was 1.5 fold greater than in tissues not exposed to methoctramine. This suggests that residual M2 receptor antagonism by methoctramine may have occurred. (2). There was no significant difference in the relaxant potency of isoprenaline in tissues pre-contracted to 2 g with either muscarinic agonists or histamine. This indicates a lack of muscarinic inhibition of isoprenaline relaxant responses. (3) In preparations pre-contracted to 3 g with L-660,863, the relaxant potency of isoprenaline was 1.7 fold less than in tissues pre-contracted with histamine (lacking M2 activity) and 7 fold greater than in tissues pre-contracted with (+ )-cisdioxolane. One explanation for all four observations is that muscarinic inhibition of B-adrenoceptors is mediated by M2 receptors that are poorly coupled. This would be predicted to have the following consequences. Firstly, residual M2 receptor antagonism (as a result of prior exposure to methoctramine) would reverse inhibitory effects of (+)-cis-dioxolane and thus increase the potency of isoprenaline. Secondly, high concentrations of agonists would be required to achieve adequate M2 receptor occupancy in order to detect a functional inhibition. Thirdly, agonists with low intrinsic efficacy at M2 receptors, such as L-660,863 or SDZ ENS 163, would behave as antagonists in such a system. Finally, antagonist occupation of a small porportion of M2 receptors would have a large effect on the functional response. However, without direct measurement of the receptor reserve associated with M2 inhibitory effects, this can only be speculated upon.
These studies have therefore provided some evidence for the involvement of M2 receptors in the inhibitory effects of (+)-cis-dioxolane on the relaxant potency of isoprenaline, although a role for M3 receptor cannot be excluded. In this respect these data concur with reports that AF-DX 116 or gallamine enhance the potency of isoprenaline in canine and rabbit trachea (Fernandes et al., 1992; Arjona et al., 1993) . In the former tissue, Mitchell et al. (1993) has also demonstrated a similar effect of pertussis toxin, which functionally uncouples M2 receptors from inhibition of adenylyl cyclase. In contrast, in bovine and guinea-pig trachea, gallamine has been reported not to augment the relaxant potency of isoprenaline Roffel et al., 1993) . The reason for these discrepancies is unclear, although differences in methodology may be important. Thus, differences in the level of basal tension, the presence or absence of epithelium or of indomethacin, and the recording of isometric or isotonic tensions may account for the differences. However, it is important to note that in guinea-pig ileum, when M3 receptors have been inactivated by alkylation, stimulation of M2 receptors causes contraction by inhibiting relaxations elicited by isoprenaline, in tissues pre-contracted to histamine (Thomas et al., 1993) . However, similar studies have yet to be reported in guinea-pig trachea.
In conclusion, these data suggest that it is the degree of muscarinic receptor activation that is important in determining the relaxant potency of isoprenaline and this is related to the efficacy of the muscarinic agonist at M2 and M3 receptors. Since muscarinic M2 receptor antagonism augments the relaxant potency of isoprenaline, these data provide some evidence for an inhibitory role of M2 receptors on relaxant responses to isoprenaline. However, the involvement of M3
receptors cannot be definitively excluded due to (a) the lack of selective M2 and M3 receptor agonists and (b) the low M2/M3 selectivity of antagonists in guinea-pig trachea.
